AIM: Neuropathological examination of both individuals in a monozygotic (MZ) twin pair with Alzheimer's disease (AD) is rare, especially in the molecular genetic era. We had the opportunity to assess the concordance and discordance of clinical presentation and neuropathology in three MZ twin pairs with AD. METHODS: The MZ twins were identified and characterised by the University of Washington Alzheimer's Disease Research Center. We reviewed the available clinical and neuropathological records for all six cases looking specifically for concordance and discordance of clinical phenotype, neuritic amyloid plaques (NP), neurofibrillary tangles (NFT) and Lewy related pathology (LRP). RESULTS: Discordance in age of onset for developing AD in the MZ twins varied from 4 to 18 years. Clinical presentations also differed between twins. One twin presented with a dementia with Lewy Body clinical syndrome while the other presented with typical clinical AD. Neuropathology within the MZ twin pairs was concordant for NP and NFT, regardless of duration of disease, and was discordant for LRP. This difference was most marked in the late onset AD twin pair. One pair was found to have a mutation in presenilin-1 (PS1) (A79V) with remarkably late onset in a family member. CONCLUSIONS: MZ twins with AD can vary considerably in age of onset, presentation and disease duration. The concordance of NP and NFT pathological change and the discordance of LRP support the concept that, in AD, the former are primarily under genetic control whereas the latter (LRP) is more influenced by disease duration and environmental factors. The A79V mutation in PS1 can be associated with very late onset of dementia.
AIM: Neuropathological examination of both individuals in a monozygotic (MZ) twin pair with Alzheimer's disease (AD) is rare, especially in the molecular genetic era. We had the opportunity to assess the concordance and discordance of clinical presentation and neuropathology in three MZ twin pairs with AD. METHODS: The MZ twins were identified and characterised by the University of Washington Alzheimer's Disease Research Center. We reviewed the available clinical and neuropathological records for all six cases looking specifically for concordance and discordance of clinical phenotype, neuritic amyloid plaques (NP), neurofibrillary tangles (NFT) and Lewy related pathology (LRP). RESULTS: Discordance in age of onset for developing AD in the MZ twins varied from 4 to 18 years. Clinical presentations also differed between twins. One twin presented with a dementia with Lewy Body clinical syndrome while the other presented with typical clinical AD. Neuropathology within the MZ twin pairs was concordant for NP and NFT, regardless of duration of disease, and was discordant for LRP. This difference was most marked in the late onset AD twin pair. One pair was found to have a mutation in presenilin-1 (PS1) (A79V) with remarkably late onset in a family member. CONCLUSIONS: MZ twins with AD can vary considerably in age of onset, presentation and disease duration. The concordance of NP and NFT pathological change and the discordance of LRP support the concept that, in AD, the former are primarily under genetic control whereas the latter (LRP) is more influenced by disease duration and environmental factors. The A79V mutation in PS1 can be associated with very late onset of dementia.
Authors: U Finckh; T Müller-Thomsen; U Mann; C Eggers; J Marksteiner; W Meins; G Binetti; A Alberici; C Hock; R M Nitsch; A Gal Journal: Am J Hum Genet Date: 2000-01 Impact factor: 11.025
Authors: M Gatz; N L Pedersen; S Berg; B Johansson; K Johansson; J A Mortimer; S F Posner; M Viitanen; B Winblad; A Ahlbom Journal: J Gerontol A Biol Sci Med Sci Date: 1997-03 Impact factor: 6.053
Authors: Debby W Tsuang; Robert G Riekse; Kristina M Purganan; Andrew C David; Thomas J Montine; Gerard D Schellenberg; Ellen J Steinbart; Eric C Petrie; Thomas D Bird; James B Leverenz Journal: J Alzheimers Dis Date: 2006-08 Impact factor: 4.472
Authors: Margaret Gatz; James A Mortimer; Laura Fratiglioni; Boo Johansson; Stig Berg; Chandra A Reynolds; Nancy L Pedersen Journal: Alzheimers Dement Date: 2006-04 Impact factor: 21.566
Authors: Margaret Gatz; Chandra A Reynolds; Laura Fratiglioni; Boo Johansson; James A Mortimer; Stig Berg; Amy Fiske; Nancy L Pedersen Journal: Arch Gen Psychiatry Date: 2006-02
Authors: R Sherrington; E I Rogaev; Y Liang; E A Rogaeva; G Levesque; M Ikeda; H Chi; C Lin; G Li; K Holman; T Tsuda; L Mar; J F Foncin; A C Bruni; M P Montesi; S Sorbi; I Rainero; L Pinessi; L Nee; I Chumakov; D Pollen; A Brookes; P Sanseau; R J Polinsky; W Wasco; H A Da Silva; J L Haines; M A Perkicak-Vance; R E Tanzi; A D Roses; P E Fraser; J M Rommens; P H St George-Hyslop Journal: Nature Date: 1995-06-29 Impact factor: 49.962
Authors: Suman Jayadev; James B Leverenz; Ellen Steinbart; Justin Stahl; William Klunk; Cheng-En Yu; Thomas D Bird Journal: Brain Date: 2010-04 Impact factor: 13.501
Authors: C Sheei-Meei Wang; J R Burke; D C Steffens; C M Hulette; J C S Breitner; B L Plassman Journal: J Neurol Neurosurg Psychiatry Date: 2009-05 Impact factor: 10.154
Authors: Diego Iacono; Inga Volkman; Inger Nennesmo; Nancy L Pedersen; Laura Fratiglioni; Boo Johansson; David Karlsson; Bengt Winblad; Margaret Gatz Journal: Brain Pathol Date: 2014-03-07 Impact factor: 6.508
Authors: Matthew Harms; Bruno A Benitez; Nigel Cairns; Breanna Cooper; Paul Cooper; Kevin Mayo; David Carrell; Kelley Faber; Jennifer Williamson; Tom Bird; Ramon Diaz-Arrastia; Tatiana M Foroud; Bradley F Boeve; Neill R Graff-Radford; Richard Mayeux; Sumitra Chakraverty; Alison M Goate; Carlos Cruchaga Journal: JAMA Neurol Date: 2013-06 Impact factor: 18.302
Authors: Gregory S Day; Erik S Musiek; Catherine M Roe; Joanne Norton; Alison M Goate; Carlos Cruchaga; Nigel J Cairns; John C Morris Journal: JAMA Neurol Date: 2016-09-01 Impact factor: 18.302